| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
1M7 does not have a specific pharmacological target. It is a chemical reagent used for RNA structural analysis rather than a therapeutic agent. The compound reacts with the 2'-hydroxyl group of RNA nucleotides, with the reactivity being dependent on the local flexibility and dynamics of the RNA structure. Flexible regions of RNA react more readily with 1M7, while rigid or structured regions show reduced reactivity. This property enables the determination of RNA secondary and tertiary structures.
|
|---|---|
| ln Vitro |
In vitro, 1M7 is used to chemically modify RNA molecules for structure probing studies. The compound selectively acylates the 2'-hydroxyl groups of flexible RNA nucleotides. The modified RNA is then analyzed by primer extension or high-throughput sequencing to identify the positions of modification. The reactivity profile provides information about RNA secondary structure, tertiary interactions, and conformational changes. 1M7 has been validated as a robust and reliable SHAPE reagent with low nucleotide bias.
|
| ln Vivo |
In vivo applications of 1M7 are limited because the compound is unsuitable for modification of intracellular RNA. It is primarily used for in vitro RNA structure probing studies. The compound's inability to penetrate cell membranes restricts its use to cell-free systems or purified RNA samples. In vivo RNA structure probing typically requires different reagents or delivery methods.
|
| Enzyme Assay |
General protocols for SHAPE analysis using 1M7 involve the following steps: RNA is denatured at 95°C for 2 minutes and then refolded in folding buffer (100 mM HEPES pH 8.0, 100 mM NaCl, 10 mM MgCl2) at 37°C for 20 minutes. 1M7 is dissolved in DMSO at a concentration of 100 mM and added to the RNA at a final concentration of 5-10 mM. The reaction is incubated at 37°C for 2-5 minutes. The reaction is stopped by ethanol precipitation or spin column purification. Modified RNA is used for primer extension with fluorescently labeled primers, followed by capillary electrophoresis or sequencing. The reactivity at each nucleotide is calculated from the peak intensities.
|
| Cell Assay |
General protocols for cell-based RNA structure analysis involve transfecting cells with RNA of interest or expressing it from a plasmid. However, 1M7 is not suitable for intracellular RNA modification. Alternative SHAPE reagents (e.g., NAI, 2-methylnicotinic acid imidazolide) that can penetrate cell membranes are used for in vivo applications. For in vitro studies, RNA is purified from cells or synthesized in vitro, then subjected to 1M7 modification as described above. The modified RNA is analyzed by primer extension, capillary electrophoresis, or next-generation sequencing.
|
| Animal Protocol |
General protocols for in vivo RNA structure probing do not typically use 1M7 due to its inability to penetrate cell membranes. Instead, cell-permeable SHAPE reagents such as NAI (2-methylnicotinic acid imidazolide) are used. For these studies, cells are treated with the reagent (50-200 mM) for 5-30 minutes at 37°C. RNA is then extracted, and the modification sites are identified by primer extension or sequencing. The reactivity profiles are used to infer RNA structures in their native cellular environment. 1M7 remains the reagent of choice for in vitro SHAPE analysis.
|
| ADME/Pharmacokinetics |
1M7 is a chemical reagent rather than a pharmaceutical agent. It has a molecular weight of 222.15 g/mol. The compound is typically stored as a solid at room temperature and dissolved in DMSO or anhydrous DMSO immediately before use. Its stability in solution is limited, and fresh solutions should be prepared for each experiment. The compound's physicochemical properties are well characterized for its use as a SHAPE reagent.
|
| Toxicity/Toxicokinetics |
1M7 is a chemical reagent and should be handled with standard laboratory safety precautions. It may cause skin and eye irritation upon contact. Inhalation of dust or vapors should be avoided. The compound should be used in a well-ventilated fume hood with appropriate personal protective equipment (gloves, safety goggles, lab coat). Toxicity data for 1M7 are limited, but it is generally considered safe for use in research laboratories when handled properly.
|
| References |
Roston TM, Dewar L, Franciosi S, Hathaway J, Bartels K, Cunningham T, Gibbs KA, Sheps S, Laksman ZWM, Sanatani S, Krahn AD. The accessibility and utilization of genetic testing for inherited heart rhythm disorders: a Canadian cross-sectional survey study. J Community Genet. 2017 Nov 23. doi: 10.1007/s12687-017-0348-y. [Epub ahead of print] PubMed PMID: 29170972.
|
| Additional Infomation |
1M7 (1-methyl-7-nitroisatoic anhydride) is a widely used SHAPE reagent for probing RNA structure. It is a chemical tool rather than a pharmaceutical drug. The compound has low nucleotide bias and is one of the most commonly used SHAPE reagents in the field. It is unsuitable for modification of intracellular RNA. 1M7 has been validated in numerous studies and is considered a gold standard for in vitro RNA structure probing. It has no therapeutic indications and is not approved for clinical use.
|
| Molecular Formula |
C9H7N2O5
|
|---|---|
| Molecular Weight |
223.164
|
| Exact Mass |
222.028
|
| CAS # |
4693-01-0
|
| Related CAS # |
4693-01-0
|
| PubChem CID |
78414
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.551g/cm3
|
| Boiling Point |
392.4ºC at 760mmHg
|
| Flash Point |
191.1ºC
|
| Index of Refraction |
1.623
|
| LogP |
0.923
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
16
|
| Complexity |
350
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(N(C)C1=CC=C([N+]([O-])=O)C=C12)OC2=O
|
| InChi Key |
FJSZPPSFHYCQHQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H6N2O5/c1-10-5-3-2-4-6(11(14)15)7(5)8(12)16-9(10)13/h2-4H,1H3
|
| Chemical Name |
1-methyl-5-nitro-2H-benzo[d][1,3]oxazine-2,4(1H)-dione
|
| Synonyms |
1M 7 1M-7 1M7
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~450.15 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.25 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (11.25 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4811 mL | 22.4054 mL | 44.8109 mL | |
| 5 mM | 0.8962 mL | 4.4811 mL | 8.9622 mL | |
| 10 mM | 0.4481 mL | 2.2405 mL | 4.4811 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05462145 | RECRUITING | Device: Globe Pulsed Field System | Paroxysmal Atrial Fibrillation Persistent Atrial Fibrillation |
Kardium Inc. | 2023-03-09 | Not Applicable |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA